Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Oil & Gas, Financials and Telecoms sectors led shares higher while losses in the Healthcare,...
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA...
Rate Cut? The CME Group is now showing a less than 50% of a chance rate cut. A pretty astonishing turn of events. The Fed Fund Futures continue to climb and are now...
ACADIA Pharmaceuticals ACAD made a monster move on Monday on good news and then pulled back. On Tuesday, it was up 2.37, or 6%, to 41.22, on 7.4 million shares. I think...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Sell||Strong Sell||BUY||Strong Buy||Strong Buy|
|Summary||Strong Sell||Strong Sell||Neutral||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Black Crows||30||1||Sep 19, 2019 03:00PM|
|Doji Star Bearish||1H||2||Sep 19, 2019 01:00PM|
|Engulfing Bearish||1M||5||Apr 19|
|Deliberation Bearish||1M||6||Mar 19|
|Doji Star Bearish||1M||6||Mar 19|
|Bank of America||29.82||30.10||29.75||-0.18||-0.60%||44.11M||18:30:00|
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.